Searchable abstracts of presentations at key conferences on calcified tissues

ba0006p086 | (1) | ICCBH2017

Feasibility and reproducibility using HRpQCTII in children and adolescents

Kent Kyla , Whalen Jessica , Strickland Ariana , Leonard Mary , Burghardt Andrew J.

We recruited 60 healthy volunteers ages 5 to 21 to perform scan-rescan precision tests on the XtremeCT II. Participants were positioned in a carbon fiber immobilization cast. iPad-based video content was used to facilitate motion-free compliance. Distal radius and tibia scans were acquired starting 2 mm proximal to the proximal margin of the growth plate or growth plate remnant. Diaphyseal radius and tibia scans were centered at an offset from the same landmark, corresponding ...

ba0006p099 | (1) | ICCBH2017

Bone strength and microarchitectural deficits in children with cystinosis

Burghardt Andrew , Kent Kyla , Long Jin , Whalen Jessica , Phelps Maira , Leonard Mary

Children with cystinosis have numerous risk factors for impaired bone accrual. We used state-of-the-art quantitative imaging of bone microarchitecture (HR-pQCT) to measure trabecular and cortical microstructure and bone strength in children and adolescents (5-20yrs) with cystinosis. We enrolled 20 cystinosis patients and recruited 34 healthy age- and gender- matched controls. Distal radius and tibia HR-pQCT scans (XtremeCT II, Scanco Medical) were acquired 2...

ba0007oc10 | (1) | ICCBH2019

Next-generation antibody-guided enzyme replacement therapy for lysosomal storage diseases

Baik Andrew , Aaron Nina , Birnbaum Matthew , Calafati Philip , Schoenherr Christopher , Economides Aris , Cygnar Katherine

Objectives: Lysosomal diseases (LDs) are a heterogenous group of 40+ genetic disorders that can affect virtually all organs and systems, including the skeletal system. They are often caused by the loss of an enzyme critical for the breakdown of macromolecules in the lysosome, leading to accumulation of these substrates and subsequent lysosomal dysfunction. Enzyme replacement therapy (ERT) is the primary treatment option for many LDs, but several issues hinder the efficacy of t...

ba0007p67 | (1) | ICCBH2019

Bone health outcomes in children and adolescents with neuromuscular disease

Biggin Andrew , Chua Verene , Wall Christie , Pacey Verity , Gray Kelly , McGee Richard , Poon Myra , Munns Craig

Objectives: To compare and contrast the natural history of osteoporosis and response to zoledronate in children and adolescents with Duchene muscular dystrophy (DMD), spinal muscular atrophy (SMA) or other congenital muscular dystrophies (CMD).Methods: A retrospective medical record review of fracture history, treatment and bone mineral densitometry of children managed at a tertiary centre in Sydney over the last 6 years.Results: A...

ba0007p90 | (1) | ICCBH2019

Osteogenesis imperfecta due to FKBP10 mutation- shift from high to low bone turnover

Lenherr-Taube Nina , Harrington Jennifer , Murphy Anne , Filipowski Kornelia , Kin On Wong Andy , Horward Andrew , Sochett Etienne

Background: Osteogenesis imperfecta (OI) due to FKBP10 mutation is a rare variant of OI. FKBP10 encodes for FKBP65, a molecular chaperon that interacts with type I procollagen to prevent premature fibril formation and plays a role in collagen crosslinking. Defects in FKBP65 result in a spectrum of moderate to severe OI with remarkable variability in phenotypes.Presenting problem: The patient is the first child of non-consanguineous Caucasian parents. She...

ba0007p146 | (1) | ICCBH2019

Does prior bisphosphonate therapy in children and adolescents with cerebral palsy alter surgical outcomes?

Fiscaletti Melissa , Loucos Robert , Jamil Kamal Abdul , Biggins Andrew , Munns Craig , Pacey Verity

Background: Children and adolescents with cerebral palsy (CP) experience musculoskeletal complications including spinal deformities, hip dysplasia and disuse osteoporosis. Bisphosphonates can improve bone mineral density, prevent fragility fractures. It is unclear if prior bisphosphonate use modifies post-operative complication in children with CP. Our aim was to compare surgical complications in children with CP with and without previous bisphosphonate treatment.<p class=...

ba0007p199 | (1) | ICCBH2019

Diversity of outcomes in randomised trials of interventions for children with osteogenesis imperfecta

McGee Richard , Wall Christie-Lee , Biggin Andrew , Pacey Verity , Poon Myra , Munns Craig

Objective: The potential for clinical trials to impact patient care may be limited if the outcomes reported vary by trial and lack direct relevance to patients. We aimed to systematically assess the scope and consistency of outcomes reported in randomised trials of interventions for children with osteogenesis imperfecta.Methods: We systematically searched for all published and unpublished randomised trials of interventions for children with osteogenesis ...

ba0007p200 | (1) | ICCBH2019

Whole body vibration training for children and adolescents with congenital myopathy

Hutchence Meghan , Pacey Verity , North Kathryn , Clarke Nigel , Rose Kristy , Biggin Andrew , Briody Julie , Munns Craig

Objectives: To evaluate the effect of 24 weeks of weight bearing vibration therapy (WBVT) on muscle strength, motor function and bone health in children with congenital myopathies.Methods: A prospective pilot study incorporating a six month observational period followed by 6 months home-based WBVT (Galileo® Pro) was undertaken. Ambulant children with congenital myopathies aged 4–16 years were eligible for inclusion. Participants were assessed a...

ba0007p212 | (1) | ICCBH2019

Genetic loss of heparanase does not inhibit osteochondromas in Ext1 and Ext2 double heterozygous hereditary multiple osteochondroma mouse model

Nannuru Kalyan , Jimenez Johanna , Brydges Susannah , Murphy Andrew , Economides Aris , Hatsell Sarah

Hereditary multiple osteochondromas (HMO) is an autosomal dominant rare genetic disorder due to LOF heterozygous mutations in EXT1 or EXT2 genes. HMO is an unmet medical condition where patients often requiring multiple surgeries. HMO is characterized by painful cartilaginous capped bony outgrowths at the growth plate (GP) regions of long bones, ribs and other skeletal elements. The molecular mechanism by which these mutations lead to disease is unknown. Mutations in EXT1 and ...

ba0002is18biog | (1) | ICCBH2013

Obesity and skeletal health

Dimitri Paul

Biographical DetailsDr P Dimitri studied Medicine at the University of St Andrew’s in Scotland and the University of Manchester where he received a medal in pathology and a distinction in Paediatrics. In 2010 he was awarded a PhD in Medicine and the Michael Blacow Award from the Royal College of Paediatrics and Child Health for his work on the relationship of fat and bone in children...